Half-year report · Q2
4564.TEDINET S100UOSE
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥356m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥695m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥708m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥709m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥548m | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥514m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥935m | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥528m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥881m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥880m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥677m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.42 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥183m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥109m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥537,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥387,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥403m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥357m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥512m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 411
| Item | Context | Value | Unit |
|---|---|---|---|
| Share based compensation expenses ope cf | Prior1YTDDuration | 7655000 | JPY |
| Share based compensation expenses ope cf | CurrentYTDDuration | － | JPY |
| Interest expenses ope cf | Prior1YTDDuration | － | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 546000 | JPY |
| Stock issuance cost ope cf | Prior1YTDDuration | 8479000 | JPY |
| Stock issuance cost ope cf | CurrentYTDDuration | 15729000 | JPY |
| Gain on reversal of subscription rights to shares ope cf | Prior1YTDDuration | -1375000 | JPY |
| Gain on reversal of subscription rights to shares ope cf | CurrentYTDDuration | -550000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 69111000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -8437000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -2602000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -114962000 | JPY |
| Decrease increase in advance payments ope cf | Prior1YTDDuration | 7041000 | JPY |
| Decrease increase in advance payments ope cf | CurrentYTDDuration | -19014000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | Prior1YTDDuration | 8615000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | CurrentYTDDuration | -28224000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | -81256000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | 64011000 | JPY |
| Increase decrease in contract liabilities ope cf | Prior1YTDDuration | -146208000 | JPY |
| Increase decrease in contract liabilities ope cf | CurrentYTDDuration | -68652000 | JPY |
| Increase decrease in income taxes payable the factor based tax ope cf | Prior1YTDDuration | 2072000 | JPY |
| Increase decrease in income taxes payable the factor based tax ope cf | CurrentYTDDuration | 73130000 | JPY |
| Other net ope cf | Prior1YTDDuration | -42011000 | JPY |
| Other net ope cf | CurrentYTDDuration | 55357000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | -877289000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -575685000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | － | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -655000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -2561000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -2425000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -879851000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -578766000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -2627000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | － | JPY |
| Payments for asset retirement obligations inv cf | Prior1YTDDuration | -70400000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | 39456000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -33570000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | － | JPY |
| Payments for long term accounts payable other fin cf | Prior1YTDDuration | － | JPY |
| Payments for long term accounts payable other fin cf | CurrentYTDDuration | -27817000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 683770000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 1174772000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYTDDuration | 3780000 | JPY |
| Repayments to share acquisition rights fin cf | Prior1YTDDuration | -6540000 | JPY |
| Repayments to share acquisition rights fin cf | CurrentYTDDuration | -1350000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 677229000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1149384000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |